- Home
- EDN vs ARQT Comparison
EDN vs ARQT Comparison
Compare EDN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- ARQT
- Stock Information
- Founded
- EDN 1992
- ARQT 2016
- Country
- EDN Argentina
- ARQT United States
- Employees
- EDN N/A
- ARQT N/A
- Industry
- EDN Electric Utilities: Central
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- ARQT Health Care
- Exchange
- EDN Nasdaq
- ARQT Nasdaq
- Market Cap
- EDN 1.3B
- ARQT 2.0B
- IPO Year
- EDN 2007
- ARQT 2020
- Fundamental
- Price
- EDN $33.22
- ARQT $16.56
- Analyst Decision
- EDN
- ARQT Strong Buy
- Analyst Count
- EDN 0
- ARQT 6
- Target Price
- EDN N/A
- ARQT $18.80
- AVG Volume (30 Days)
- EDN 105.5K
- ARQT 2.7M
- Earning Date
- EDN 03-11-2025
- ARQT 05-13-2025
- Dividend Yield
- EDN N/A
- ARQT N/A
- EPS Growth
- EDN 42.19
- ARQT N/A
- EPS
- EDN 0.30
- ARQT N/A
- Revenue
- EDN $1,981,694,257.00
- ARQT $196,542,000.00
- Revenue This Year
- EDN $51.74
- ARQT $56.60
- Revenue Next Year
- EDN N/A
- ARQT $43.62
- P/E Ratio
- EDN $6.88
- ARQT N/A
- Revenue Growth
- EDN 33.82
- ARQT 229.74
- 52 Week Low
- EDN $13.78
- ARQT $6.99
- 52 Week High
- EDN $51.69
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- EDN 52.08
- ARQT 66.30
- Support Level
- EDN $31.20
- ARQT $16.80
- Resistance Level
- EDN $34.78
- ARQT $17.75
- Average True Range (ATR)
- EDN 2.00
- ARQT 1.11
- MACD
- EDN 0.38
- ARQT 0.20
- Stochastic Oscillator
- EDN 76.64
- ARQT 87.94
Stock Price Comparison Chart: EDN vs ARQT
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.